Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522284 | PMC |
| http://dx.doi.org/10.18632/oncotarget.18562 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CCR4+Tfh2 cells specifically produce IL-4 driving the pathological reaction in IgG4-related disease.
Clin Exp Rheumatol
November 2024
Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Objectives: Human T follicular helper (Tfh) cells are classified into three subsets: Tfh1, Tfh2, and Tfh17 cells. Among them,Tfh2 cells are defined as CXCR3-negative and CCR6-negative, and may contain diverse cell populations. We examined whether CCR4 serves as a marker for identifying Tfh2 cells that produce interleukin (IL)-4 and its involvement in IgG4-related disease (IgG4-RD).
View Article and Find Full Text PDFPublisher Correction: Translation efficiency driven by CNOT3 subunit of the CCR4-NOT complex promotes leukemogenesis.
Nat Commun
October 2024
Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada.
[Drug-related exanthema under immunotherapy and targeted oncological therapy].
Dermatologie (Heidelb)
June 2024
Klinik für Dermatologie, Allergologie und Venerologie, Universitätsmedizin Essen, Hufelandstr. 55, 45122, Essen, Deutschland.
Background: Oncological therapies can cause a variety of mucocutaneous adverse events. Exanthematous adverse events can be challenging in the context of the urgent need for cancer treatment due to their spread, sometimes rapid progression, and mucous membrane or organ involvement.
Materials And Methods: This article provides an overview of the most important exanthematic dermatoses as side effects of modern drug-based tumor therapies with diagnostic and therapeutic information for clinicians, taking into account the current literature and guidelines.
Correction: CKLF1 Aggravates Focal Cerebral Ischemia Injury at Early Stage Partly by Modulating Microglia/Macrophage Toward M1 Polarization Through CCR4.
Cell Mol Neurobiol
May 2024
State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica & Neuroscience Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.
CNOT6: A Novel Regulator of DNA Mismatch Repair.
Cells
February 2022
Center for Healthy Aging, University of Copenhagen, Copenhagen, DK-2200 Copenhagen, Denmark.
DNA mismatch repair (MMR) is a highly conserved pathway that corrects both base-base mispairs and insertion-deletion loops (IDLs) generated during DNA replication. Defects in MMR have been linked to carcinogenesis and drug resistance. However, the regulation of MMR is poorly understood.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!